Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
89.6M
-
Number of holders
-
169
-
Total 13F shares, excl. options
-
75.2M
-
Shares change
-
-1.45M
-
Total reported value, excl. options
-
$364M
-
Value change
-
-$7.27M
-
Put/Call ratio
-
2.47
-
Number of buys
-
89
-
Number of sells
-
-69
-
Price
-
$4.84
Significant Holders of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) as of Q3 2024
199 filings reported holding VERV - Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2024.
Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) has 169 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 75.2M shares
of 89.6M outstanding shares and own 83.9% of the company stock.
Largest 10 shareholders include Alphabet Inc. (12.3M shares), BlackRock, Inc. (7.28M shares), MILLENNIUM MANAGEMENT LLC (4.96M shares), STATE STREET CORP (4.25M shares), VANGUARD GROUP INC (4.01M shares), Casdin Capital, LLC (4M shares), T. Rowe Price Investment Management, Inc. (2.43M shares), Schonfeld Strategic Advisors LLC (2.41M shares), Novo Holdings A/S (2.4M shares), and ARCH Venture Management, LLC (2.01M shares).
This table shows the top 169 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.